Exam 1: Dynamics Flashcards
Pharmacodynamics
study of physiological and biochemical interaction of drug molecules with target tissue that is responsible for ultimate effects of drug
Large protein molecules located on cell surface/within cells that are initial sites of action of biological active agents
receptor
Two types of receptors
cell surface-extracellular
Intracellular: cytoplasm/nucleus
Most hormones that acat on brain to influence neural events use ___ receptor
intracellular
high affinity
attach most readily
low effiacy
can attach, but doesn’t do anything
antagonist
block effect
agonist
act as NT
Partial agonists
efficacy less than full agonists, but more than antagonist
-effect, but not as much
Technically some intrinsic activity
Inverse agonists
initiate biological action, but action is opposite to agonist
Receptor number modification
long term regulation:
up-regulation: increase receptors
down regulation: decrease receptors
Receptors modified in sensitivity
more rapid regulation via 2nd messengers
The idea that receptor proteins have different characteristics in different target tissue
receptor subtypes
Does response curve
describes the extent of biological/behavioral effect (mean response in population) produced by given [drug]
ED50
dose that produces 1/2 maximal effect
ED100
maximum response occurs at does which we assume receptors fully occupied
Potency
absolute amount of drug necessary to produce a specific effect
maximum on y-axis
efficacy
TD50
does at which 50% of the population experiences a particular toxic effect
Therapeutic index
TI= TD50 / ED50
LD50 / ED 50
Factor index
dose of drug that is lethal to 1% of the population compared with the dose that is therapeutically effective in 99% of the population (LD1 / ED99)
Competitive Antagonists
can be displaced from sites by excess of agonist because increase [drug] competes more effectively for fixed receptors
Noncompetitive antagonists
drugs that reduce effects of agonists in ways other than competing for the receptor.
e.i. binding to portion of receptor other than agonist binding site
Physiological antagonism
two drugs that act in 2 distinct ways but interact in such a way that they reduce each other’s effectiveness in the body
Potentiation
situation in which combo of 2 drugs produces effects that are greater than the sum of their individual effects.
Radioligand binding
used to study number of receptors in given region
Radioligand: to measure amount of ligand that binds to sites we are concerned with, add
very high [nonradioactive competing ligand] to some tubes to show most radioactive binding displaced.
radioligand: ___ binding subtracted when data for specific binding calculated
nonspecific
Saturability
finite # receptors in tissue.
Point at which binding curve plateus
Bmax
If you compare rate of dissociation with rate of binding, you get ___
Kd
Kd
dissociation constant, measure of drug affinity for specific receptor
Autoradiogarphy
use radio ligand on slides instead of ground up tissue
shows radio bound ligand and its location, good fro studying effects of brain lesions.
In vivo receptor binding
shows researcher where particular drug/NT binds in intact animal
Dose response curves only show
POTENCY
Increase potency
decrease ED50 (EC50?)
Increase potency
lower x-axis value
Increase efficacy
increase Bmax
Factors determining drug potency
1) Accessibility (kinetics)
2) affinity (dynamics)
3) intrinsic activity (dynamics)
affinity
drug binds to receptors
quantitative measure of attraction between drug molecules and receptors
intrinsic activity
cellular response
k1
D + R –> DR
Rate at which drug ASSOCIATES with receptor
k2
DR –> D + R
Rate at which drug DISSOCIATES from receptor
how do you measure drug affinity?
3H radio ligand label
Substitute 3H (tritium) in for hydrogen
Tritium= PNN
QNB
binds to acetylcholine mucurinic receptors
Beta particle emission: radio isotope
Tritium PNN unstable, so decays to helium-3 PPN
Radioligand receptor binding is…
transient, reversible, selective
saturable, displacement
increase affinity:
k1 ___
k2 ___
k1 fast
k2 slow
kd =
k2/k1
kd (dissociation), how do we determine?
saturation experiment
[radioligand] that labeled 50% receptor in sample
Ki (inhibition constant), how do we determine?
Competition experiment, [drug] that displaces 50% of radio ligand bound in sample
Affinity of drug for receptor
Kd
total number of receptors
Bmax
Saturation experiment
3H ligand
tissue prep
incubation for 1 hour
total binding = Specific binding (SB) +NSB (bound to membrane)
T= total binding SB = T - NSB
Y-axis: SRB
x-axis: [radioligand]
Increase affinity means ____ Kd
lower Kd
Competition experiment: radioactive form of drug not available
allows direct comparison of affinities of several different drugs
Same as saturation, but now varied amounts of competitor ligand too
y-axis: % SB of RL
x-axis: log [competitor] M
increasing affinity
decrease KI
Intrinsic Activity:
activation of cellular activity by drug
Agonist
increase affinity, mimic NT (similar cell response)
fully/partially stimulate receptors (intrinsic activity)
Antagonist
Increase affinity, block receptors (no NT response)
no intrinsic activity, don’t stimulate receptors
NO INTRINSIC ACTIVITY
Affinity
molecular attraction between drug and receptor
Intrinsic Activity
Activation of Cellular activity by drug
Partial + Full agonist
weaker than if just full
Primary site of drug action
synapse
3 Ways to remove a transmitter
1) Enzymes
2) Reuptake
3) Glial Reuptake
Ionotropic Receptors
Fast synaptic transmission (ms)
Subunits around central ion
ions go through
Ionotropic examples
acetylcholine
GABA-A
5-HT3
Metabotropic
cell surface receptors regulate activity
Slower (s)
peptides
alpha/beta subunits activate effectors
Agonist receptor bind > Gprotein dissociation
PHOSPHORYLATION
G sub salpha
increase phosphorylation
G sub i
decrease phosphorylation
Metabotropic receptor examples
Acetylcholine [M], monoamines, peptides
M2/M4
Increase K+ influx
Decrease adenylyl cyclase
M1/M3/M5
increase phosphoinositide
What can phosphorylation do?
receptor up down regulation ion channel open/close Enzyme activation/deactivation Neurotransmitter release dendritic growth cell metabolism
Amino acid NT
Glutamate GABA Glycine
Monoamines
Dopamine, Norepinephrine, Epinephrine, and Serotonin
Peptides
Opioids, Orexin, CRF, BDNF
Novel/Gases
NO, CO, H2S
Purines
ATP, Adenosine
Catecholamines
D, N, E
Indoleamine
Serotonin